@article{a12cdc93f8924247bf10812c00092e81,
title = "Current and Future Treatment of Peanut Allergy",
abstract = "Based on productive translational research programs conducted over the last 20 years, the clinical landscape of peanut allergy is now rapidly changing. In this review, we review data from recent trials of investigational peanut oral and epicutaneous immunotherapies, explore the pipeline of novel therapies in early development, and identify future research needs and priorities.",
keywords = "Anaphylaxis, Desensitization, Peanut allergy, Quality of life, Sustained unresponsiveness, Tolerance",
author = "Vickery, {Brian P.} and Motohiro Ebisawa and Shreffler, {Wayne G.} and Wood, {Robert A.}",
note = "Funding Information: Disclosure of Relevant Financial Relationships with Commercial Interests: B. P. Vickery declares consultancy and membership on Scientific Advisory Board, Aimmune Therapeutics; and membership on Outcomes Research Advisory Board, Food Allergy Research and Education. M. Ebisawa declares membership on Scientific Advisory Board, DBV Technologies. W. G. Shreffler declares membership on Scientific Advisory Board, Aimmune Therapeutics; consultancy, DBV Techniologies; and consultancy, Sanofi. R. A. Wood declares research support from the National Institutes of Allergy and Infectious Disease, DBV Technologies, Aimmune Therapeutics, Regeneron, Sanofi, Astellas, and HAL-Allergy. M. Schatz declares no relevant conflicts of interest. Funding Information: Conflicts of interest: B. P. Vickery declares consultancy and membership on Scientific Advisory Board, Aimmune Therapeutics; and membership on Outcomes Research Advisory Board, Food Allergy Research and Education. M. Ebisawa declares membership on Scientific Advisory Board, DBV Technologies. W. G. Shreffler declares membership on Scientific Advisory Board, Aimmune Therapeutics; consultancy, DBV Techniologies; and consultancy, Sanofi. R. A. Wood declares research support from the National Institute of Allergy and Infectious Diseases , DBV Technologies , Aimmune Therapeutics , Regeneron , Sanofi , Astellas , and HAL-Allergy . Review and Feature Article Funding Information: Conflicts of interest: B. P. Vickery declares consultancy and membership on Scientific Advisory Board, Aimmune Therapeutics; and membership on Outcomes Research Advisory Board, Food Allergy Research and Education. M. Ebisawa declares membership on Scientific Advisory Board, DBV Technologies. W. G. Shreffler declares membership on Scientific Advisory Board, Aimmune Therapeutics; consultancy, DBV Techniologies; and consultancy, Sanofi. R. A. Wood declares research support from the National Institute of Allergy and Infectious Diseases, DBV Technologies, Aimmune Therapeutics, Regeneron, Sanofi, Astellas, and HAL-Allergy. Publisher Copyright: {\textcopyright} 2018 American Academy of Allergy, Asthma & Immunology",
year = "2019",
month = feb,
doi = "10.1016/j.jaip.2018.11.049",
language = "English (US)",
volume = "7",
pages = "357--365",
journal = "Journal of Allergy and Clinical Immunology: In Practice",
issn = "2213-2198",
publisher = "Elsevier",
number = "2",
}